ArticleThe AAPS journal2025
Drug Dissolution Enhancement Using 3D-Printed Silica-Based Oral Films.
Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orodispersible films (ODFs) are increasingly employed for individualized drug delivery due to their ease of administration and precise dosing. However, their drug loading capacity is often limited by the need to maintain thin, flexible structures, posing a particular challenge for incorporating poorly soluble drugs. This study aimed to develop and characterize porous ODF matrices optimized for 3D printing of medicated inks. The primary objective was to investigate the impact of macroporosity on the dissolution kinetics of both poorly soluble and readily soluble drugs, with a focus on enhancing the release of the poorly soluble dexamethasone. Porous ODFs were fabricated via solvent casting using silica- and silicate-based porogens, then loaded with caffeine or dexamethasone through 3D printing. The films were comprehensively characterized using structural (micro-CT, BET), mechanical, and solid-state techniques (SEM, Raman microscopy, FTIR, XRD) to assess porosity, drug crystallization behavior, and drug-matrix compatibility. Drug release was evaluated through dissolution studies. Silica-based porogens yielded films with tunable macroporosity, supporting high drug loads (up to 3-5 times the ink volume). Dexamethasone printed on the SY2 substrate exhibited markedly enhanced dissolution (79.2 ± 1.8%) compared to its powdered form (29.9 ± 11.5%), achieving 61.5% release within 20 min. In contrast, caffeine (readily soluble) showed a transient reduction in dissolution rate during the initial two minutes, attributed to increased particle size and delayed film disintegration. Overall, integrating porous matrix design with 3D printing significantly improved the dissolution of poorly soluble dexamethasone without inducing drug-matrix interactions, confirming that structural modifications drive the enhanced release.
Indexed as
Identifiers
41361598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.